Notice of retraction of two articles (“Infliximab in patients with primary Sjögren's syndrome: A pilot study” and “Infliximab in patients with primary Sjögren's syndrome: one-year followup”)

Authors

  • Serge D. Steinfeld MD, PhD,

  • Paul Demols MD,

  • Isabelle Salmon MD, PhD,

  • Robert Kiss PhD,

  • Thierry Appelboom MD, PhD

Errata

This article corrects:

  1. Infliximab in primary Sjögren's syndrome: One-year followup Volume 46, Issue 12, 3301–3303, Article first published online: 12 December 2002

Two articles from Arthritis & Rheumatism, “Infliximab in patients with primary Sjögren's syndrome: a pilot study” by Steinfeld SD, Demols P, Salmon I, Kiss R, and Appelboom T (published online on October 12, 2001) and “Infliximab in patients with primary Sjögren's syndrome: one-year followup” by Steinfeld SD, Demols P, and Appelboom T (published online on December 12, 2002) in Wiley Online Library (wileyonlinelibrary.com) have been retracted by agreement between the authors, the American College of Rheumatology, the journal Editor-in-Chief, and Wiley Periodicals, Inc. In these articles we reported on an open-label study that appeared to demonstrate that infliximab treatment was effective in patients with primary Sjögren's syndrome. We regretfully report that some methodologic errors in the treatment of the data were discovered. In fact, the results of the study did not demonstrate an effect of infliximab in Sjögren's syndrome. Consequently, the results reported in these articles should be disregarded.

In these articles we reported on an open-label study that appeared to demonstrate that infliximab treatment was effective in patients with primary Sjögren's syndrome. We regretfully report that some methodologic errors in the treatment of the data were discovered. In fact, the results of the study did not demonstrate an effect of infliximab in Sjögren's syndrome. Consequently, the results reported in these articles should be disregarded.

Ancillary